SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback